UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2017
Commission File Number 001-36866
SUMMIT THERAPEUTICS PLC
(Translation of registrants name into English)
136a Eastern Avenue
Milton Park, Abingdon
Oxfordshire OX14 4SB
United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
FORM 20-F ☒ FORM 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:
YES ☐ NO ☒
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):
On April 12, 2017, Summit Therapeutics plc (the Company) issued a press release announcing that it had granted share options to certain officers and employees of the Company under its 2016 Long Term Incentive Plan. The related press release is attached hereto as Exhibit 99.1.
The information in this Report on Form 6-K, including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SUMMIT THERAPEUTICS PLC | ||
By: | /s/ Erik Ostrowski | |
Erik Ostrowski Chief Financial Officer |
Date: April 13, 2017
EXHIBIT INDEX
Exhibit |
Description | |
99.1 | Press release dated April 12, 2017 |
Exhibit 99.1
Summit Therapeutics plc
(Summit, the Company, or the Group)
GRANT OF SHARE OPTIONS TO DIRECTORS/PDMRS
Oxford, UK, 12 April 2017Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces the following option grants over new ordinary shares of 1p nominal value (Ordinary Shares) were made on 11 April 2017 to Directors, PDMRs and employees in line with the Companys Long Term Incentive Plan.
Mr Glyn Edwards, the Companys Chief Executive Officer, was granted options over 762,764 Ordinary Shares. These options have an exercise price of 185 pence per share and will vest in full on 23 June 2019 subject to achievement of performance conditions pertaining to corporate and programme development milestones. This option award to Glyn Edwards was due to be made in 2016, during the Companys normal granting cycle, but was deferred due to insufficient headroom in the Companys Long Term Incentive Plan.
Dr David Roblin, the Companys Chief Operating Officer and President of Research and Development, was granted options over 324,324 Ordinary Shares. These options have an exercise price of 185 pence per share and will vest in full on 11 April 2020 subject to achievement of performance conditions pertaining to corporate and programme development milestones.
A further grant of options over 150,436 Ordinary Shares was made to other employees of the Company. These options will vest in nine equal tranches on a quarterly basis from 11 April 2018 and will vest in full on 11 April 2020.
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
Summit Therapeutics Glyn Edwards / Richard Pye (UK office) Erik Ostrowski / Michelle Avery (US office) |
Tel: +44 (0)1235 443 951 +1 617 225 4455 | |
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson |
Tel: +44 (0)20 7213 0880 | |
N+1 Singer (Broker) Aubrey Powell / Lauren Kettle |
Tel: +44 (0)20 7496 3000 | |
MacDougall Biomedical Communications (US media contact) Karen Sharma |
Tel: +1 781 235 3060 ksharma@macbiocom.com | |
Consilium Strategic Communications (Financial public relations, UK) Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Lindsey Neville |
Tel:+44(0)2037095700 summit@consilium-comms.com |
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name | Mr Glyn Edwards | ||||
2 | Reason for the notification | |||||
a) | Position / status | Chief Executive Officer | ||||
b) | Initial notification / Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Summit Therapeutics plc | ||||
b) | LEI | 213800NRW8AOMYMTBD89 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument | Ordinary shares of 1 pence each |
||||
Identification code | GB00BN40HZ01 | |||||
b) | Nature of the transactions | Grant of share options | ||||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
185 pence per share (exercise price) |
762,764 | |||||
d) | Aggregated information | |||||
- Aggregated volume | N/A | |||||
- Price | ||||||
e) | Date of the transaction | 11 April 2017 | ||||
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||
a) | Name | Dr David Roblin | ||||||
2 | Reason for the notification | |||||||
a) | Position / status | Chief Operating Officer and President of Research and Development |
||||||
b) | Initial notification / Amendment | Initial notification | ||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name | Summit Therapeutics plc | ||||||
b) | LEI | 213800NRW8AOMYMTBD89 | ||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
a) | Description of the financial instrument, type of instrument | Ordinary shares of 1 pence each | ||||||
Identification code | GB00BN40HZ01 | |||||||
b) | Nature of the transactions | Grant of share options | ||||||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||||
185 pence per share (exercise price) | 324,324 | |||||||
d) | Aggregated information | |||||||
- Aggregated volume | N/A | |||||||
- Price | ||||||||
e) | Date of the transaction | 11 April 2017 | ||||||
f) | Place of the transaction | Outside a trading venue |
-END-
P Q:YR]WA Y6@@Q6@@Y
M6L;&SF-[C#E*4N_W_R%*:P@Q4@@Q2EI[G,;>]R$Y4A Q2IREM<[&SAA":P@Y
M:P@Q8Q Q:[W6WD)SG#%KE#EKG'N